

CITATION REPORT

List of articles citing

Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer

DOI: 10.1111/j.1464-410x.2009.08652.x
BJU International, 2009, 104, 1592-8.

Source: <https://exaly.com/paper-pdf/46394413/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
66	Robotic-assisted laparoscopic prostatectomy. <i>British Journal of Cancer</i> , 2009 , 101, 1491-6	8.7	26
65	The quality-of-life impact of prostate cancer treatments. <i>Current Urology Reports</i> , 2010 , 11, 139-46	2.9	29
64	The effect of prostate-specific antigen screening during the last decade: development of clinicopathological variables independently of the biopsy core number. <i>BJU International</i> , 2010 , 106, 1293-7	5.6	7
63	Current world literature. <i>Current Opinion in Supportive and Palliative Care</i> , 2010 , 4, 207-27	2.6	
62	Prostate cancer screening: current status and future perspectives. <i>Nature Reviews Urology</i> , 2010 , 7, 487-93	9.3	57
61	Should prostate-specific antigen screening be offered to asymptomatic men?. <i>Expert Review of Anticancer Therapy</i> , 2010 , 10, 1043-53	3.5	4
60	Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. <i>European Journal of Cancer</i> , 2010 , 46, 3095-101	7.5	109
59	PSA testing for prostate cancer improves survival--but can we do better?. <i>Lancet Oncology</i> , 2010 , 11, 702-3	21.7	10
58	Disproportionate presentation of high risk prostate cancer in a safety net health system. <i>Journal of Urology</i> , 2010 , 184, 1931-6	2.5	16
57	Absolute Quantitation of DNA Methylation of 28 Candidate Genes in Prostate Cancer Using Pyrosequencing. <i>Disease Markers</i> , 2011 , 30, 151-161	3.2	70
56	Peroxiredoxin 2 in the nucleus and cytoplasm distinctly regulates androgen receptor activity in prostate cancer cells. <i>Free Radical Biology and Medicine</i> , 2011 , 51, 78-87	7.8	37
55	The impact of socio-economic circumstances on overall and grade-specific prostate cancer incidence: a population-based study. <i>British Journal of Cancer</i> , 2012 , 107, 575-82	8.7	21
54	International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy. <i>British Journal of Cancer</i> , 2012 , 107, 1467-73	8.7	22
53	Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer. <i>Advances in Urology</i> , 2012 , 2012, 368528	1.6	5
52	[Circulating tumor cells and advanced prostate cancer]. <i>Bulletin Du Cancer</i> , 2012 , 99 Suppl 1, S4-15	2.4	1
51	Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. <i>Annals of Internal Medicine</i> , 2012 , 157, 120-34	8	1468
50	Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era. <i>Urology</i> , 2012 , 79, 626-31	1.6	35

49	Effect of prostate-specific antigen screening on metastatic disease burden 10 years after diagnosis. <i>Urology</i> , 2012 , 80, 367-72	1.6	6
48	East meets West: ethnic differences in prostate cancer epidemiology between East Asians and Caucasians. <i>Chinese Journal of Cancer</i> , 2012 , 31, 421-9		83
47	Anatomy of the prostate revisited: implications for prostate biopsy and zonal origins of prostate cancer. <i>Histopathology</i> , 2012 , 60, 142-52	7.3	42
46	Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. <i>European Urology</i> , 2012 , 61, 1132-8	10.2	95
45	General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations. <i>BJU International</i> , 2012 , 110, 24-7	5.6	7
44	Patient knowledge about prostate-specific antigen (PSA) and prostate cancer in Australia. <i>BJU International</i> , 2012 , 109 Suppl 3, 52-6	5.6	4
43	Radiotherapy and surgery for high-risk localized prostate cancer: a UK questionnaire survey of urologists and clinical oncologists. <i>BJU International</i> , 2012 , 110, 608-12	5.6	3
42	Causes of death in men with prostate cancer: an analysis of 50,000 men from the Thames Cancer Registry. <i>BJU International</i> , 2013 , 112, 182-9	5.6	23
41	Molecular imaging of prostate cancer with PET. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1685-8	8.9	65
40	Future prospects: who is the patient who still dies of prostate cancer following local treatment of high-risk prostate cancer? Can we prolong their lives using modern treatment approaches?. <i>Current Opinion in Urology</i> , 2013 , 23, 372-6	2.8	2
39	Gleason grade progression is uncommon. <i>Cancer Research</i> , 2013 , 73, 5163-8	10.1	60
38	Changing presentation of prostate cancer in a UK population--10 year trends in prostate cancer risk profiles in the East of England. <i>British Journal of Cancer</i> , 2013 , 109, 2115-20	8.7	26
37	DNA methylation gene-based models indicating independent poor outcome in prostate cancer. <i>BMC Cancer</i> , 2014 , 14, 655	4.8	15
36	Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners. <i>Prostate Cancer and Prostatic Diseases</i> , 2014 , 17, 157-62	6.2	
35	Nationwide, population-based study of prostate cancer stage migration between and within clinical risk categories. <i>Scandinavian Journal of Urology</i> , 2014 , 48, 426-35	1.6	27
34	DNA methylation of PITX2 predicts poor survival in men with prostate cancer. <i>Biomarkers in Medicine</i> , 2014 , 8, 1143-50	2.3	16
33	Risk adapted chemoprevention for prostate cancer: an option?. <i>Recent Results in Cancer Research</i> , 2014 , 202, 79-91	1.5	5
32	Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1109-18	21.7	157

31	Prostate Cancer Prevention. <i>Recent Results in Cancer Research</i> , 2014 ,	1.5	5
30	Audit of PSA requesting practices in primary care compared to guidelines established by the Prostate Cancer Risk Management programme in the Avon region of the South West of England. <i>Journal of Clinical Urology</i> , 2014 , 7, 45-54	0.2	0
29	The status of surgery in the management of high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2014 , 11, 342-51	5.5	28
28	An early-detection programme for prostate cancer in Saudi men: A call from a tertiary-care centre in the Eastern province. <i>Arab Journal of Urology Arab Association of Urology</i> , 2014 , 12, 187-91	1.7	8
27	Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink. <i>Cancer Causes and Control</i> , 2014 , 25, 33-43	2.8	20
26	Trends and outcome from radical therapy for primary non-metastatic prostate cancer in a UK population. <i>PLoS ONE</i> , 2015 , 10, e0119494	3.7	18
25	Delay from biopsy to radical prostatectomy influences the rate of adverse pathologic outcomes. <i>Prostate</i> , 2015 , 75, 1085-91	4.2	28
24	Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma. <i>BMC Cancer</i> , 2017 , 17, 158	4.8	12
23	Low-risk Prostate Cancer: Identification, Management, and Outcomes. <i>European Urology</i> , 2017 , 72, 238-249	4.2	42
22	Reply to Mieke Van Hemelrijck, Hans Garmo, Jan Adolfsson, and Pē Stattin. Letter to the Editor re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. <i>Eur Urol</i> 2016;70:56-61. <i>European Urology</i> , 2017 , 71, e63	10.2	
21	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. <i>European Urology</i> , 2017 , 71, 381-388	10.2	25
20	The Burden of Healthcare Costs Associated with Prostate Cancer in Ireland. <i>Global & Regional Health Technology Assessment</i> , 2017 , 4, grhta.5000249	0.2	
19	High-intensity Focused Ultrasound of the Prostate. 2018 , 1567-1579		
18	Clinical Significance of Multiparametric Magnetic Resonance Imaging as a Preoperative Predictor of Oncologic Outcome in Very Low-Risk Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	2
17	Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. <i>BMC Urology</i> , 2019 , 19, 19	2.2	21
16	Prostate cancer in young men: An emerging young adult and older adolescent challenge. <i>Cancer</i> , 2020 , 126, 46-57	6.4	34
15	Surgery for pathological T3a, T3b and lymph node positive, prostate cancer: surgical, functional and oncological outcomes. <i>Journal of Clinical Urology</i> , 2020 , 205141582095820	0.2	
14	Circulating cell-free DNA: Translating prostate cancer genomics into clinical care. <i>Molecular Aspects of Medicine</i> , 2020 , 72, 100837	16.7	4

13	Temporal changes in cause-specific death in men with localised prostate cancer treated with radical prostatectomy: a population-based, nationwide study. <i>Journal of Surgical Oncology</i> , 2021 , 124, 867-875	2.8	1
12	Sociodemographic index and global trends in prostate cancer: 1990-2017. <i>Prostate</i> , 2021 , 81, 825-831	4.2	2
11	Prostate-specific antigen screening of men with lower urinary tract symptoms (opportunistic screening) and of asymptomatic men undergoing executive health check: an audit from two institutions. <i>Indian Journal of Urology</i> , 2021 , 37, 159-162	0.8	
10	Perioperative complications of radical retropubic prostatectomy in patients with locally advanced prostate cancer: a comparison with clinically localized prostate cancer. <i>Asian Journal of Andrology</i> , 2013 , 15, 241-5	2.8	6
9	Socio-economic inequalities in survival of patients with prostate cancer: role of age and Gleason grade at diagnosis. <i>PLoS ONE</i> , 2013 , 8, e56184	3.7	18
8	The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance. <i>Oncotarget</i> , 2016 , 7, 82783-82797	3.3	21
7	Changes in pathologic outcomes and operative trends with robot-assisted laparoscopic radical prostatectomy. <i>Indian Journal of Urology</i> , 2014 , 30, 378-82	0.8	6
6	Health-Related Quality of Life Changes in Prostate Cancer Patients after Radical Prostatectomy: A Longitudinal Cohort Study. <i>Cancer Research and Treatment</i> , 2019 , 51, 556-567	5.2	8
5	The importance of combined radiation and endocrine therapy in locally advanced prostate cancer. <i>Asian Journal of Andrology</i> , 2012 , 14, 245-6	2.8	2
4	Management of High-Risk/Locally Advanced Disease. 2013 , 831-842		
3	Update on Diagnostic Criteria, on Biopsy and Surgical Specimen: Preinvasive Lesions, from Epithelial Cell Hyperplasia to Carcinoma In Situ and Invasive Carcinoma [First-Line Immuno-Phenotyping of Prostate Diseases. 2013 , 3-42		
2	Conditional Relative Survival and Competing Mortality of Patients with Prostate Cancer in Korea: A Nationwide Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 326-334	4	
1	Relationship between ethnicity and stage at diagnosis in England: a national analysis of six cancer sites. 2023 , 13, e062079		0